Castle Biosciences (CSTL) Interest Expenses (2018 - 2026)

Castle Biosciences has reported Interest Expenses for 9 years, with the latest figure at $8.2 million in Q2 2026.

• Quarterly Interest Expenses rose 38814.29% year-over-year to $8.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.2 million (up 4246.81% YoY) and the FY2025 annual result came in at $48.7 million, down 3.63% from the prior year.
• Interest Expenses fell to $8.2 million in Q2 2026 per CSTL's latest filing, from $9.3 million in the prior quarter.
• Over five years, Interest Expenses peaked at $48.2 million in Q1 2022 and troughed at -$51000.0 in Q4 2024.
• A 5-year average of $6.0 million and a median of $235500.0 in 2024 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2024 and 2026: Interest Expenses tumbled 2650.0% in 2024, then surged 54382.35% in 2026.
• Over 5 years, Interest Expenses stood at $1.3 million in 2022, then sank by 99.84% to $2000.0 in 2023, then sank by 2650.0% to -$51000.0 in 2024, then jumped by 147.06% to $24000.0 in 2025, then jumped by 33950.0% to $8.2 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $8.2 million, $9.3 million, and $24000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.